Replies to post #4513 on RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Hi Erik, Asenapine is apparently a dog, and Pfizer bailed on it. Organon has $5 bil in other ongoing revenues though, so I guess a $14 bil price tag for the company isn't too unreasonable even if Asenapine flops. I wonder if Schering will try to get out of the NIMH/TURNS committment?